MedTrace Logo

Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis

NCT03308045 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-03-10

No results posted yet for this study

Summary

Primary objective: safety and tolerability

Secondary objectives: additional indicators of long term safety and indicators of clinical activity

Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and biomarkers

Conditions

  • Non-infectious Uveitis

Interventions

BIOLOGICAL

pEYS606

pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle

Sponsors & Collaborators

  • Eyevensys

    lead INDUSTRY

Principal Investigators

  • Antoine AB BREZIN, MD · Hôpital Cochin - Paris - France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03308045 on ClinicalTrials.gov